TOT BIOPHARM-B (01875): Zhang Qian has been appointed as the Chairman of the Remuneration Committee.

TOT BIOPHARM-B (01875) announced that the company's independent non-executive Director Mr. Zhang Qian has been appointed to the remuneration committee ...

Zhitong FinanceMar 21 20:56

TOT BIOPHARM-B (1875.HK): Achieved profitability for the first time, with positive operating cash flow for three consecutive years.

Event: In 2024, the performance turned a profit for the first time, with net cash from operating activities positive for three consecutive years. The report summary shows the first profit, and net cash from operating activities has been continuously positive for three years. The company's performance in 2024 turned a profit for the first time.

National Certificate InternationalMar 19 00:00

East Sun Pharmaceutical (01875.HK): A breakthrough player in the ADC market, can the international quality system unlock profit growth?

When the market anchors the valuation of the CDMO Industry in terms of scale and profitability, Dongyao Pharmaceutical is building a little-known "hidden value growth curve" – establishing a globally leading capacity and quality management system to create global Business capabilities and harvest more opportunities for Business development. 1. The overlooked trump card: establishing a competitive moat with an international standard quality system. In the Capital Markets' conventional understanding of CDMO enterprises, capacity scale and cost advantages are often seen as core valuation factors. However, the latest annual report from Dongyao Pharmaceutical reveals that a more strategically profound plan is unfolding around it.

Gelonghui FinanceMar 17 08:57

All the way up! The Innovative Drugs Sector in Hong Kong stocks surged collectively, with multiple stocks doubling this year. Who is reshaping the valuation?

The rise in the Hong Kong stock market's Innovative Drugs Sector continues. Market analysts point out that this wave of Innovative Drugs momentum benefits from a combination of factors including market sentiment, policy, and the realization of the companies' own commercial value.

Securities TimesMar 13 09:50

TOT BIOPHARM-B (01875.HK): Sun Hui, Zhang Qian, and Gu Xuelin have each been appointed as independent non-executive Directors.

Gelonghui, March 12, regarding TOT BIOPHARM-B (01875.HK), announced that effective from March 12, 2025: (i) Hu Lan has resigned from the position of independent non-executive director, chairman of the audit and related party transaction review committee, and member of the nomination committee due to the expiration of his three-year term and his desire to devote more time to other matters; (ii) Zhang Hongren has resigned from the position of independent non-executive director, member of the audit and related party transaction review committee, and member of the remuneration committee due to the expiration of his three-year term and his desire to devote more time to other matters; (iii) Wang Deqian due to the expiration of the three-year term.

Gelonghui FinanceMar 12 21:46

TOT Biopharm Turns to Yearly Profit for First Time in 2024 as Revenue Soars 41%; Shares Down 3%

MT NewswiresMar 12 12:02